Second-generation antipsychotics show higher response rates than placebo for augmenting major depressive disorder
Antipsychotics show promise in treating major depressive disorder
This meta-analysis of 13,616 adults with major depressive disorder evaluated pharmacological augmentation with lithium, triiodothyronine (T3…
Adding specific antipsychotic medications to treatment plans may help adults with major depressive disorder achieve better results than a pl…
Semaglutide Improves Metabolic Health in Schizophrenia Patients on Antipsychotics
Semaglutide improves blood sugar and weight in people with schizophrenia and prediabetes
A randomized, placebo-controlled trial in 154 overweight or obese individuals with schizophrenia and prediabetes receiving second-generation…
A new trial shows semaglutide helps lower blood sugar and reduce weight in people with schizophrenia who also have prediabetes or obesity.
Systematic review and meta-analysis finds 50% prevalence of antipsychotic polypharmacy in MENAT/EMRO countries
Half of Schizophrenia Patients Take Multiple Drugs at Once
This systematic review and meta-analysis of 17 studies (6,053 individuals) from MENAT/EMRO countries found a pooled prevalence of antipsycho…
New data reveals half of patients with schizophrenia in the Middle East take multiple antipsychotic drugs at once.